77671-30-8

Upstream product

• 1192-34-3 4-methyl-1,3-dihydro-imidazol-2-one 
• 28141-24-4 4-hydroxybenzoyl chloride 
• 77671-29-5 1,3-dihydro-4-(4-methoxybenzoyl)-5-methyl-2H-imidazol-2-one 
• 721966-65-0 4-methyl-5-{[4-(phenylmethoxy)phenyl]carbonyl}-4-imidazolin-2-one 

Downstream Products

• 1381768-14-4 4-methyl-5-{[4-(oxiran-2-ylmethoxy)phenyl]carbonyl}-4-imidazolin-2-one 
• 721966-68-3 ethtyl 2-{4-[(5-methyl-2-oxo-4-imidazolin-4-yl)carbonyl]phenoxy}acetate 

Relevant academic research and scientific papers

COMPOUNDS WITH MIXED PDE-INHIBITORY AND β-ADRENERGIC ANTAGONIST OR PARTIAL AGONIST ACTIVITY FOR TREATMENT OF HEART FAILURE

This invention provides compounds that possess inhibitory activity against β--adrenergic receptors and phosphodiesterase PDE, including phosphodiesterase 3 (PDE3 ). This invention further provides pharmaceutical compositions comprising such -compounds; methods of using such compounds for treating cardiovascular disease, stroke, epilepsy, ophthalmic disorder or migraine; and methods of preparing pharmaceutical compositions and compounds that possess inhibitory activity against ?-adrenergic receptors and PDE.

CARDIOTONIC COMPOUNDS WITH INHIBITORY ACTIVITY AGAINST β-ADRENERGIC RECEPTORS AND PHOSPHODIESTERASE

The present invention provides compounds possessing inhibitory activity against (3-adrenergic receptors and phosphodiesterase (PDE), including type 3 phosphodiesterase (PDE-3). The present invention further provides pharmaceutical compositions comprising

4-Aroylimidazol-2-ones and their use as pharmaceuticals

Novel 4-aroylimidazol-2-ones of the following general structure which are useful as antihypertensives, cardiotonics, antithrombotics, bronchodilators and uterospasmolytics STR1 wherein Ar is 2-furyl, 2-thienyl or phenyl, the latter of which may optionally

4-Aroyl-1,3-dihydro-2H-imidazol-2-ones, a new class of cardiotonic agents

A series of 4-aroyl-1,3-dihydro-2H-imidazol-2-ones was synthesized and evaluated for pharmacological activity in the anesthetized dog. Most members of this series produced dose-related increases in cardiac contractile force as well as relatively minor inc